Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +41.70%
#2 0G 0G +28.35%
#3 Fake World Assets Fake World Assets +21.19%
#4 Nockchain Nockchain +19.03%
#5 Full Moon Full Moon +17.70%
#6 Zora Zora +17.60%
#7 SAFEcoin SAFEcoin +17.38%
#8 Notcoin Notcoin +16.69%
#9 Axelar Axelar +15.62%
#10 ADO Protocol ADO Protocol +15.45%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Kedudukan dalam Saham #13173
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Harga Saham
$8.46
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$514.33M
Perubahan (1 hari)
-2.08%
Perubahan (1 tahun)
128.03%
Negara
US
Perdagangan Kyverna Therapeutics, Inc. (KYTX)

Kategori

Healthcare
Pendapatan untuk Kyverna Therapeutics, Inc. (KYTX)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Kyverna Therapeutics, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Kyverna Therapeutics, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH